Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bemobi 2020 earnings release

2020 Highlights Despite the negative economic impact associated with COVID , Bemobi had a solid 2020 with YoY growth in all key financial and operational metrics: · Net Revenue of R$ 241.1 million, 9% higher than that in 2019. · EBITDA of R$ 93.4 million in 2020, 11% higher than 2019. · Net Income was 23% higher year-over-year, reaching R$ 39.8 million. · We reached 72 carriers – of which 20 are managed by Bemobi Loop – in 38 countries. · We maintained an average of 34 million subscriptions in the different types of services during 2020. · In the microfinance segment

Teleste Oyj – Managers’ Transactions – Tianta Oy

TELESTE CORPORATION MANAGERS’ TRANSACTIONS 30.3.2021 AT 09:00 Teleste Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tianta Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Korpimies, Vesa Position: Member of the Board Issuer: Teleste Oyj LEI: 743700CJRQRU0007GN59 Notification type: INITIAL NOTIFICATION Reference number: 743700CJRQRU0007GN59_20210329171650_2 _________________________________________

ERAS® – A Success from the Nurse’s Perspective

A newly published article based on a survey among ERAS® Nurses, brings up factors such as improving patient outcomes and satisfaction being rated as main motivators for an ERAS® implementation. Further, in order to sustain a successful ERAS® Implementation, factors such as continuous staff education and coordination beyond the implementation period, appear to be of utmost importance.Suggestions for a sustainable ERAS® program were 1) resources for continuous training, 2) regular feedback on ERAS® compliance for team motivation and 3) discuss state-of-the-art publications for evidence-

Raisio plc: Raisio's converted shares

Raisio plc     Stock Exchange Release, 30 March 2021 RAISIO'S CONVERTED SHARES The Board of Directors of Raisio plc has decided in its meeting held on 15 March 2021 to convert a total of 179,968 restricted shares (series K) into free shares (series V). The decision has been entered in the Trade Register today, on 30 March 2021. The additional lot of free shares in question is admitted to trading on the Nasdaq Helsinki Ltd as of 31 March 2021. Since the beginning of 2021, a total of 179,968 restricted shares of the company have been converted into free shares. The number of issued

Addnode Group acquires the software company S-GROUP Solution

STOCKHOLM, March 30, 2021 - Addnode Group has signed an agreement to acquire the software company S-GROUP Solutions AB (“S-GROUP Solutions”). The company had sales of SEK 144 million and an EBITDA result of SEK 27 million in the financial year 2020. The acquisition strengthens Addnode Group's market-leading position in Sweden within municipal technology systems and geodata-based solutions for the smart city.S-GROUP Solutions specializes in business-related GIS solutions for municipalities, water and sewage organizations and Lantmäteriet, the Swedish mapping, cadastral and land registration

Notice of annual general meeting 2021 in Camurus AB (publ)

The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the annual general meeting on 6 May 2021. The Board of Directors has decided that the annual general meeting should be conducted by way of postal vote pursuant to temporary legislation being in effect in 2021. This means that the annual general meeting will be held without the physical presence of shareholders, representatives or third parties. The shareholders will therefore only be able to exercise their voting rights by postal voting in the manner prescribed below. Information on the resolutions

Unique AI method for generating proteins will speed up drug development

  Artificial Intelligence is now capable of generating novel, functionally active proteins, thanks to recently published work by researchers from Chalmers University of Technology, Sweden. “What we are now able to demonstrate offers fantastic potential for a number of future applications, such as faster and more cost-efficient development of protein-based drugs,” says Aleksej Zelezniak, Associate Professor at the Department of Biology and Biological Engineering at Chalmers. Proteins are large, complex molecules that play a crucial role in all living cells, building,

iioote and Hey IOT partner for SMART CITY, SMART BUILDING and SMART INDUSTRY applications in Germany

iioote today announced it has signed a partnership agreement with Hey IOT, an experienced IoT enabler in the German Cyber Valley, to establish sustainable SMART INFRASTRUCTURE Solutions with cities, authorities and enterprises. iioote’s unique platform WebIoT will form the foundation with data from Sensors deployed in buildings, cities, industries, transport & tracking, and agriculture. Implementing these leading solutions Hey IOT will create sustainable value, protect infrastructure and grow the businesses of their clients. With most global economies now engaged in using IoT

IMF: Scant transparency for COVID-19 emergency loans

Anti-corruption measures a step forward, but weak implementationThe International Monetary Fund (IMF), despite overall progress in its anti-corruption efforts, has not ensured sufficient oversight of its COVID-19 emergency loans, Human Rights Watch and Transparency International said today. As a result, it is hard for members of the public in many countries to track the governments’ COVID-19 spending, to identify potential corruption or to determine whether the deprivation of basic rights connected to the pandemic is being addressed. Human Rights Watch and Transparency International

Diös acquires another office building in Borlänge

It has just been announced that Diös will acquire a modern office building on Humanistgatan in Borlänge. Existing tenants in the fully occupied building include Sweco, Skanska, Mockfjärds and Borlänge local authority. The agreed property value amounts to SEK 80 million. The seller is Fastighets AB Hushagen and transfer of ownership will take place on 1 June. The acquired office building on Humanistgatan in Borlänge. This acquisition complements and strengthens Diös’ suite of attractive offices in Borlänge. The property is strategically located, close to Dalarna Science Park and

Picosun Group demonstrates strong growth in 2020

ESPOO, Finland, 30[th] of March 2021 – Picosun Group reports strong growth and a positive operating profit from its fiscal year 1.1.2020-31.12.2020.  Fiscal year 2020 in short* · Order intake grew by 48,4% and was €40,9M (€27,5M) · Turnover grew by 38,6% and was €37,6M (€27,1M) · Operating profit was €0,9M (€-0,3M), which is 2,5% (-1,1%) of the turnover A bigger portion of the new order intake and turnover, compared to previous years, consisted of sales of machines meant for production in the industry and medical sector. The growth was especially strong in Asia and Europe.

Africa Oil Announces its Year-End 2020 Statement of Reserves with a 117% 2P Reserves Replacement Ratio and the Posting of its First ESG Review

VANCOUVER, BC, March 29, 2021 /CNW/ - (TSX – AOI)  (Nasdaq Stockholm – AOI)    Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) is pleased to announce the posting of its 2020 statement of reserves on SEDAR (www.sedar.com) as part of its Annual Information Form. This disclosure is based on an independent reserves evaluation, effective 31 December 2020, prepared by RISC (UK) Limited (“RISC”) for Africa Oil in accordance with Canadian National Instrument 51-101 – Standards for Oil and Gas Activities ("NI 51-101") and the Canadian Oil and Gas Evaluation Handbook ("COGE Handbook"). Africa

Kallelse till extra bolagsstämma i Divio Technologies AB (publ)

Styrelsen i Divio Technologies AB (”Bolaget”) kallar härmed till en extra bolagsstämma tisdagen den 13 april 2021 klockan 08.00 Skeppargatan 27 i Stockholm.AnmälanAktieägare skall för att få delta i stämman dels vara införd i den av Euroclear Sweden AB förda aktieboken torsdagen den 1 april 2021, dels anmäla sitt deltagande till Bolaget senast onsdagen den 7 april 2021 per post på adress Divio Technologies AB, Skeppargatan 27, 114 52 Stockholm eller per e-mail jon.levin@divio.ch. Vid anmälan bör uppges namn, personnummer/organisationsnummer samt registrerat aktieinnehav. Aktieägare som

Immunovia reports positive results of the blinded clinical validation of IMMray[TM] PanCan-d blood test in USA

Stage I/II pancreatic cancers were detected with 98% specificity and 85% sensitivity in familial/hereditary risk group cohorts LUND, SWEDEN ―Immunovia today announced the successful completion of the last development milestone of IMMray™ PanCan-d blood test designed for early detection of pancreatic cancer (PDAC). The blinded validation study data demonstrated that Immunovia’s IMMray™ PanCan-d biomarker signature and CA 19-9 detects early stage I&II pancreatic cancers with a test specificity/sensitivity of 98%/85% vs familial/hereditary controls (reference PanFAM clinicaltrials.gov (

Immunovia reports improved test performance of IMMray[TM] PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients

Stage I/II pancreatic cancer was detected with a specificity of 92% and a sensitivity of 80% in a clinical study LUND, SWEDEN ― Immunovia today announced improved performance of its blood based IMMray™ PanCan-d biomarker signature together with CA 19-9, in a clinical retrospective study. The study was designed to evaluate detection of early stage pancreatic cancer in high risk patients with non-specific but concerning symptoms. The study data demonstrate that Immunovia’s test  now detects pancreatic cancers (all stages) with 92% specificity and 81% sensitivity for this cohort, which is

Transfer of treasury shares in Ratos AB (publ)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.The board of Ratos AB (publ) ("Ratos" or the “Company”) has today resolved, pursuant to the authority granted by the annual general meeting on 10 March 2021, to transfer 4,430,762 Class B treasury shares in Ratos, representing 1.37% of the total number of shares outstanding and 0.41% of the total number of votes in the Company. The shares have been transferred to Carnegie Fonder

Genovis CFO has resigned

Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately. “During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors,” says Fredrik Olsson, CEO of Genovis

Herantis Pharma to focus on CDNF and xCDNF programs

Herantis Pharma Plc Company release, Inside Information   29 March 2021 at 9:00 PM EET Herantis Pharma Plc (“Herantis or the Company”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis’ CDNF and xCDNF assets and to commence seeking out-licensing partners for the Lymfactin[®] program in the treatment of Breast Cancer Related Lymphedema (BCRL).  As previously announced in a press release on March 2, 2021 that while a favourable

Hansa Biopharma enters preclinical research collaboration with argenx

Collaboration to evaluate potential combination of companies’ IgG-modulating approachesLund, Sweden March 29, 2021 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that they have entered into a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies’ IgG-modulating technologies. The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod,

SRV Group Plc’s Board of Directors resolved share-based incentive plans for key personnel

SRV GROUP PLC     STOCK EXCHANGE RELEASE     29 MARCH 2021    20.45 EET SRV Group Plc’s Board of Directors resolved share-based incentive plans for key personnel The Board of Directors of SRV Group Plc has resolved to establish a new share-based Long-Term Incentive Plan 2021–2025 and a share-based One-off Long-Term Incentive Plan 2021–2022 directed to the Group key personnel. The Long-Term Incentive Plans aim to combine the objectives of the shareholders and the key personnel in order to increase the value of the Company in the long-term, and to strengthen the key personnel’s

SpectrumOne publishes prospectus relating to the rights issue of Units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELASE WOULD BE ILLEGAL OR REQUIRE FURTHER REGISTRATION OR OTHER MEASURES. THIS PRESS RELASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF SPECTRUMONE AB (PUBL). PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW. SpectrumOne AB (publ) (“SpectrumOne” or the “Company)” today publishes a prospectus (the “Prospectus”) in

Organisation of SRV Group Plc’s Board of Directors and composition of Board Committees

SRV GROUP PLC     STOCK EXCHANGE RELEASE     29 MARCH 2021    20.15 EET Organisation of SRV Group Plc’s Board of Directors and composition of Board Committees SRV Group Plc’s Annual General Meeting held earlier today elected Tomi Yli-Kyyny as Chairman of the Board. In its organising meeting, SRV Group Plc’s Board of Directors has elected a Vice Chairman and the members of its Board Committees for a term ending at the closing of the Annual General Meeting in 2022. Timo Kokkila was elected as Vice Chairman of the Board of Directors. Heli Iisakka was elected as Chairman and

TR-1 - Replacement

The following announcement replaces the 'TR-1' announcement released on 29 March 2021. The indirect number of voting rights attached to shares, stated under Section 8A, has been amended to 116,036,866. All other details remain unchanged. The full amended text is shown below.   TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(to besent to the relevantissuer and tothe FCA in MicrosoftWord format ifpossible)[i] 1a. Identity of the Independentissuer or the

Simon-Erik Ollus appointed Executive Vice President, Generation and member of Fortum Executive Management

FORTUM CORPORATION STOCK EXCHANGE RELEASE 29 MARCH 2021 AT 20:01 EEST  Simon-Erik Ollus, M.Soc.Sc. (Econ.), 42, has been appointed Executive Vice President of Fortum’s Generation division and member of Fortum’s Executive Management starting on 29 March 2021. He is succeeding Tiina Tuomela who is appointed the new CFO of Uniper and consequently has stepped down from her position at Fortum. In his new position, Mr Ollus will report to the President and CEO Markus Rauramo.  Simon-Erik Ollus has been with Fortum since 2009 and held various roles in strategy and market intelligence and has

There are no items matching the current filter
There are no more items matching the current filter
Back to top